表紙
市場調查報告書

中樞神經系統 (CNS) 治療藥監測:醫療設備的開發平台評估

Central Nervous Systems Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 916557
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
中樞神經系統 (CNS) 治療藥監測:醫療設備的開發平台評估 Central Nervous Systems Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年11月01日內容資訊: 英文 49 Pages
簡介

本報告提供全球中樞神經系統 (CNS) 治療藥監測市場上的主要開發中產品及其臨床實驗的進展調查,產品的功能、特性比較分析 (臨床實驗的各進展階段) ,及主要企業、組織的簡介及代表性產品,近來的市場動靜 (業績報告、資本交易趨勢等) 等資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 中樞神經系統 (CNS) 治療藥的監測:概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期

第4章 中樞神經系統 (CNS) 治療藥監測:臨床實驗中的開發中產品,各企業

  • 中樞神經系主導療藥監測的企業:各臨床實驗階段的開發中產品
  • 中樞神經系主導療藥監測:各臨床實驗階段的開發中產品

第5章 中樞神經系主導療藥監測市場:企業、產品概要

  • Abbott Diagnostics
    • 開發中產品和,現在進行中的臨床實驗的概要
  • ARK Diagnostics Inc
  • Avacta Group Plc
  • ELITechGroup Inc
  • Nipro Europe N.V.
  • Pax Neuroscience Inc
  • Saladax Biomedical Inc
  • Siemens Healthineers AG
  • University of Colorado

第6章 中樞神經系統 (CNS) 治療藥監測市場:目前的趨勢

第7章 附錄

目錄
Product Code: GDME0803EPD

GlobalData's Medical Devices sector report, "Central Nervous Systems Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019" provides an overview of Central Nervous Systems Therapeutic Drug Monitoring currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Central Nervous Systems Therapeutic Drug Monitoring pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Central Nervous Systems Therapeutic Drug Monitoring under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Central Nervous Systems Therapeutic Drug Monitoring and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Central Nervous Systems Therapeutic Drug Monitoring under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Central Nervous Systems Therapeutic Drug Monitoring Overview 6

3 Products under Development 7

  • 3.1 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 7
  • 3.2 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Territory 8
  • 3.3 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path 9
  • 3.4 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date 10

4 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products under Development by Companies 11

  • 4.1 Central Nervous Systems Therapeutic Drug Monitoring Companies - Pipeline Products by Stage of Development 11
  • 4.2 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 12

5 Central Nervous Systems Therapeutic Drug Monitoring Companies and Product Overview 13

  • 5.1 Abbott Diagnostics Company Overview 13
    • 5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 13
  • 5.2 ARK Diagnostics Inc Company Overview 14
    • 5.2.1 ARK Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.3 Avacta Group Plc Company Overview 18
    • 5.3.1 Avacta Group Plc Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.4 ELITechGroup Inc Company Overview 22
    • 5.4.1 ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.5 Nipro Europe N.V. Company Overview 25
    • 5.5.1 Nipro Europe N.V. Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.6 Pax Neuroscience Inc Company Overview 26
    • 5.6.1 Pax Neuroscience Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.7 Saladax Biomedical Inc Company Overview 27
    • 5.7.1 Saladax Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.8 Siemens Healthineers AG Company Overview 28
    • 5.8.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.9 University of Colorado Company Overview 32
    • 5.9.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 32

6 Central Nervous Systems Therapeutic Drug Monitoring- Recent Developments 33

  • 6.1 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 33
  • 6.2 Jul 29, 2019: Siemens Healthineers continues to drive growth forward 33
  • 6.3 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers 34
  • 6.4 May 02, 2019: Siemens Healthineers posts strong revenue and profit growth in the second quarter 35
  • 6.5 Apr 09, 2019: Avacta Group: Interim results for the period ended 31 January 2019 36
  • 6.6 Feb 11, 2019: Siemens Healthineers to invest EUR 350 million in new Campus Forchheim 38
  • 6.7 Jan 28, 2019: Avacta Group names Dr. Sam Williams as Non-Executive Director to the Board 39
  • 6.8 Jan 21, 2019: Avacta Group announced its AGM business update and notice of results 39
  • 6.9 Dec 12, 2018: Avacta Group names Dr. Jose Saro as Chief Medical Officer 41
  • 6.10 Dec 04, 2018: 10 Billion Lab Tests and Growing: Siemens Healthineers Mass. Manufacturing Expansion Largely Completed 41
  • 6.11 Dec 04, 2018: 10 billion lab tests and growing: Siemens Healthineers mass. Manufacturing expansion largely completed 43
  • 6.12 Nov 05, 2018: Siemens Healthineers with strong finish in fourth quarter, full year targets for fiscal 2018 achieved 43
  • 6.13 Oct 23, 2018: Leading Homegrown Medical Group, MWH Medical partners Siemens Healthineers to launch region's first Asia Reference Centre 44

7 Appendix 46

  • 7.1 Methodology 46
  • 7.2 About GlobalData 49
  • 7.3 Contact Us 49
  • 7.4 Disclaimer 49

List of Tables

  • Table 1: Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 7
  • Table 2: Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Territory 8
  • Table 3: Central Nervous Systems Ther

List of Figures

  • Figure 1: Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 7
  • Figure 2: Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Territory 8
  • Figure 3: Central Nervous Systems
Back to Top